Skip to Main Content
CWRU Links


Daniel J.  Lindner, MD, PhD

Daniel J. Lindner, MD, PhD

Director, Athymic Animal & Xenograft Core 216.445.0548 (o) 216.636.2498 (f)

Assistant Professor, Cancer Biology
Member, Developmental Therapeutics Program

Daniel J. Linder, MD, PhD joined the staff of the Lerner Research Institute in 1999. He started in the Center for Cancer Drug Discovery & Development, a part of the Department of Cancer Biology. Since then, Dr. Linder has worked in the Department of Translational Hematology & Oncology Research, also in the Department of Cancer Biology, and the Department of Molecular Medicine in the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Dr. Linder received a bachelor’s degree in biology from the Massachusetts Institute of Technology in 1977 and an MD from Georgetown University in 1981. He also received a PhD in microbiology from the Medical College of Wisconsin in1996. He has had residency and fellowship in Oregon Health Sciences University and the Medical College of Wisconsin, respectively. Dr. Linder has won the Innovator Award at Cleveland Clinic in 2004, 2007, and 2008. He is currently an assistant professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University (Molecular Medicine).

View External Profile

View Publications

His research involves the study of mechanisms of acquired drug resistance in renal cancer, and development of more effective drugs to treat myelodysplastic syndrome and acute myelogenous leukemia.

Dr. Lindner’s research in the Athymic Animal & Xenograft Core deals with the research utilizing human and mouse tumor models, angiogenesis (growth of blood vessels stimulated by tumors) and pharmacokinetics (the movement and metabolism of drugs in the body). Animal experiments are routinely conducted in the Athymic Animal & Xenograft Core, including research on mouse and human tumor models.

renal cancer, drug resistance, myelodysplastic syndrome, leukemia, acute myelogenous leukemia, tumors, tumor models, angiogenesis, pharmacokinetics, IP6K2, TKI